There are other means to measure risk such as fundamental analysis, which can give you insight to any issues that could b arising. Also, you can just look and analyze a chart using indicators and technical analysis to determine the possible risk at your point of entry. Not only is there Beta, but there are many other Greek symbols that can be used, but be sure to read up on what each one means. If you ever get stuck, reach out to an investing community and then can help to explain it and help you through any misunderstandings.
Beta
 | By Nathan Young | Macroaxis Story |
Beta is the measurement of how an equity or product moves with the underlying instrument it is attached with. Beta is measured as follows, if a product has a Beta of 1 or above, than the product is more volatile, but if it falls below 1, it will be less volatile. When a Beta is at 1, that means it will move in rhythm with the asset it is tied with. For example, the ETF ticker SPY that follows the S&P 500 will have a Beta near 1 because it is supposed to follow the S&P 500 Index. Conversely, if you invest in an inverse ETF, it will likely be near a 0 Beta because it moves in the opposite direction of the market it is intended to follow.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Ellen Johnson
If you’re looking to measure risk, Beta is the Greek data point you want to use. When building a portfolio or looking at ETF products, a good way to judge how the risk factor may be is to compare Beta levels. If you want a portfolio that tracks the market, then you want it to be closer to 1, but if you are looking for more volatility, then you can exceed the 1 market for greater movements when the market moves.
How important is Altamira Therapeutics's Liquidity
Altamira Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Altamira Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Altamira Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Altamira Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Altamira Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Altamira Therapeutics's total debt and its cash.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Nathan Young do not own shares of Altamira Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.